Dendreon Announces Webcast Presentation at ROTH Conference

Tue Mar 12, 2013 7:00pm EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130312:nBw126646a

SEATTLE--(Business Wire)--
March 12, 2013-Dendreon Corporation (NASDAQ:DNDN) today announced that
management will present at the 25th Annual ROTH Conference in Laguna Niguel,
California, on March 18, 2013, at 11:00 a.m. PT. 

The presentation will be webcast live and available for replay from Dendreon's
website, www.dendreon.com. If you are unable to listen to the live webcast, it
will be archived on the site following the presentation. To access the replay,
go to the Investor Relations section of the website. 

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development, commercialization
and manufacturing of novel therapeutics. The Company applies its expertise in
antigen identification, engineering and cell processing to produce active
cellular immunotherapy (ACI) product candidates designed to stimulate an immune
response in a variety of tumor types. Dendreon's first product, PROVENGE®
(sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in
April 2010. Dendreon is exploring the application of additional ACI product
candidates and small molecules for the potential treatment of a variety of
cancers. The Company is headquartered in Seattle, Washington, and is traded on
the NASDAQ Global Market under the symbol DNDN. For more information about the
Company and its programs, visit http://www.dendreon.com/.

Dendreon Corporation
Corporate Communications
Lindsay Rocco, 862-596-1304
media@dendreon.com
or
Dendreon Corporation
Investor Relations
Nicole Soley, 206-455-2384
InvestorRelations@dendreon.com

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.